Q32 Bio Inc (QTTB)
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologics aimed at restoring healthy immune balance in autoimmune and inflammatory diseases linked to immune dysfunction. Its lead program, Bempikibart (ADX-914), is a fully human monoclonal antibody targeting interleukin-7 receptor alpha; it has completed Phase 2a clinical testing and is being evaluated for conditions including atopic dermatitis and alopecia areata. The company is also advancing ADX-096, a C3d mAb-CR1 fusion protein intended for ophthalmologic applications, along with other C3d-based fusion proteins and nanobody programs designed for tissue-targeted complement inhibition. Q32 Bio was founded in 2017 and is headquartered in Waltham, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-QTTB
|
$8.59
|
-18.7% Downside
|
Overvalued
|
$42.25
|
299.7% Upside
|
Bargain
|
Great
|
0.0%
|
November 5, 2026
|
9.2x
|
2.9x
|
5.8x
|
314.7 M
|
210.7 M
|
1.7%
|
48.5%
|
18.4
|
-58.7%
|
